Q3 2024 Earnings Call Transcript November 14, 2024 Emily Bodnar – H.C. Wainwright: Operator: Thank you for standing by. I ...
Mink Therapeutics, Inc. ( (INKT) ) has released its Q3 earnings. Here is a breakdown of the information Mink Therapeutics, Inc. presented to ...
Operating Burn Reduction: Nearly 60% reduction from the same time last year. MiNK Therapeutics Inc (NASDAQ:INKT) has made significant advancements in their iNKT cell therapy platform, which is ...
Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on MiNK Therapeutics (INKT – Research Report) and keeping the price target at $9.00. Emily Bodnar’s rating is based on several ...
AgenT-797 combined with bispecific engagers targeting antigens such as MUC16, HER2, Claudin 18.2, and DLL3, promote increased ...
Analysts are estimating that MiNK Therapeutics will report an earnings per share (EPS) of $-0.08. The announcement from MiNK Therapeutics is eagerly anticipated, with investors seeking news of ...
CiRA researchers found that reprogramming one type of iNKT cells to iPS cells and then differentiating them back results in reprogrammed iNKT cells (re-iNKT cells) that show properties of another ...
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of ...
PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback